EU regulators back a bladder cancer gene therapy and two lung cancer drugs

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended five new medicines for EU-wide marketing authorization following its 23–26 March meeting, with the agency publishing the outcome on 27 March [s1]. Three of the five carry orphan drug designation, the EU's classification for treatments of rare conditions, and a fourth is built for pediatric use specifically [s1]. A CHMP positive opinion is not itself a marketing authorization — it is a scientific recommendation that the European Commission then acts on, typically issuing a formal decision within roughly two months, but it is the pivotal regulatory step that determines whether a medicine reaches the EU market at all.

A gene therapy for bladder cancer that doesn't respond to standard treatment

The committee recommended conditional marketing authorization for Adstiladrin (nadofaragene firadenovec), sponsored by Ferring Pharmaceuticals A/S, for adults with high-grade, BCG-unresponsive non-muscle invasive bladder cancer [s1]. BCG — Bacillus Calmette-Guérin — is the standard first-line intravesical therapy for this type of bladder cancer; patients whose tumors stop responding to it have historically had few options short of bladder removal. A conditional marketing authorization allows a medicine onto the market on the basis of more limited data than a standard authorization would require, on the condition that the manufacturer completes further studies — a mechanism the EU reserves for treatments addressing unmet medical needs where the balance of risk and benefit favors earlier access.

Two different drugs for the same hard-to-treat lung cancer

Extensive-stage small cell lung cancer — an aggressive cancer that has already spread beyond the lung and chest at diagnosis — picked up two separate positive opinions at this meeting, for two different roles in its treatment.

Imdylltra (tarlatamab), from Amgen Europe B.V., received a recommendation for treating extensive-stage small cell lung cancer directly, carrying orphan designation on the basis of the disease's poor prognosis and the limited treatment options available to patients who progress on standard chemotherapy [s1]. Separately, Zepzelca (lurbinectedin), from Pharma Mar S.A., was recommended specifically for maintenance treatment in the same patient population — meaning use after initial chemotherapy has controlled the disease, intended to delay progression rather than treat active disease — and also carries orphan designation [s1].

The two recommendations describe complementary uses rather than competing ones: one drug positioned for treating the cancer, the other for holding it in remission afterward. Small cell lung cancer's aggressive course and historically poor five-year survival have made it a persistent target for exactly this kind of sequential drug development.

A rare immune disorder, and a pediatric heart and kidney drug

Joenja (leniolisib), from Pharming Technologies B.V., received a recommendation for treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), a rare inherited immune disorder [s1]. The recommendation is for approval under exceptional circumstances — a designation the EU applies when a disease is rare enough that comprehensive data may never be obtainable — restricted to patients aged 12 and older weighing at least 45 kilograms [s1].

The fifth recommendation, Bopediat (furosemide), from Proveca Pharma Limited, is for treating edema and hypertension in children from birth to under 18 years old who have chronic kidney disease [s1]. Furosemide itself is a long-established diuretic; what CHMP recommended here is a paediatric-use marketing authorization, a designation created specifically to bring formulations and dosing evidence tailored to children onto the market for a drug whose adult use is already well established [s1]. The application was processed as a hybrid submission, meaning it relies in part on data from an already-authorized reference medicine [s1].

Why the EU's slower path still matters

None of these five medicines is a therapy Europeans are encountering for the first time globally — several already have marketing history in other jurisdictions under the same brand names, arriving in the EU on the Committee's own regulatory timeline rather than simultaneously with other markets. That gap between a medicine's first global approval and its EU authorization is a routine feature of pharmaceutical regulation, not a sign of problems with any individual drug, but it does mean EU patients with these conditions have been waiting on a separate clock. For the bladder cancer and small cell lung cancer indications in particular — diseases where treatment options for advanced or unresponsive cases remain limited — a positive opinion is the signal that the wait is nearly over, pending the European Commission's decision.

What to watch

The European Commission's decisions on all five recommendations are expected within roughly two months of the CHMP opinion, the EU's standard post-recommendation timeline, and are near-formalities in practice — the Commission rarely departs from CHMP's scientific recommendation. Once authorized, each medicine still faces a separate, member-state-by-member-state process for pricing and reimbursement decisions, which in the EU's decentralized system can take considerably longer than the marketing authorization itself and will determine how quickly patients can actually access any of these five treatments.

Sources

• Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 23-26 March 2026 — European Medicines Agency, 27 March 2026